PT3360864T - Composto de pirimidina - Google Patents

Composto de pirimidina

Info

Publication number
PT3360864T
PT3360864T PT168536860T PT16853686T PT3360864T PT 3360864 T PT3360864 T PT 3360864T PT 168536860 T PT168536860 T PT 168536860T PT 16853686 T PT16853686 T PT 16853686T PT 3360864 T PT3360864 T PT 3360864T
Authority
PT
Portugal
Prior art keywords
pyrimidine compound
pyrimidine
compound
Prior art date
Application number
PT168536860T
Other languages
English (en)
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of PT3360864T publication Critical patent/PT3360864T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • C07D239/49Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
PT168536860T 2015-10-07 2016-10-06 Composto de pirimidina PT3360864T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015199750 2015-10-07

Publications (1)

Publication Number Publication Date
PT3360864T true PT3360864T (pt) 2021-06-02

Family

ID=58487860

Family Applications (2)

Application Number Title Priority Date Filing Date
PT211646401T PT3868741T (pt) 2015-10-07 2016-10-06 Composição compreendendo um composto de pirimidina e um antigénio derivado de agente patogénico
PT168536860T PT3360864T (pt) 2015-10-07 2016-10-06 Composto de pirimidina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT211646401T PT3868741T (pt) 2015-10-07 2016-10-06 Composição compreendendo um composto de pirimidina e um antigénio derivado de agente patogénico

Country Status (21)

Country Link
US (3) US10632192B2 (pt)
EP (2) EP3868741B1 (pt)
JP (3) JP6769976B2 (pt)
KR (1) KR102651207B1 (pt)
CN (1) CN108290845B (pt)
AU (1) AU2016334826B2 (pt)
CA (1) CA3001283C (pt)
CY (1) CY1124542T1 (pt)
DK (2) DK3360864T3 (pt)
ES (2) ES2870679T3 (pt)
FI (1) FI3868741T3 (pt)
HK (1) HK1255921A1 (pt)
HU (2) HUE055079T2 (pt)
MY (1) MY194902A (pt)
PH (1) PH12018500755A1 (pt)
PL (2) PL3868741T3 (pt)
PT (2) PT3868741T (pt)
RU (1) RU2759917C2 (pt)
SG (1) SG11201802832UA (pt)
TW (1) TWI718188B (pt)
WO (1) WO2017061532A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016334826B2 (en) * 2015-10-07 2020-08-27 Sumitomo Pharma Co., Ltd. Pyrimidine compound
SG11201903042VA (en) 2016-10-14 2019-05-30 Precision Biosciences Inc Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
JP2020510619A (ja) * 2016-12-16 2020-04-09 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated ミカファンギン組成物
EP3603619A4 (en) 2017-03-29 2020-12-09 Sumitomo Dainippon Pharma Co., Ltd. VACCINAL ADJUVANT FORMULATION
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
AU2018392213B2 (en) 2017-12-20 2021-03-04 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
JP7296398B2 (ja) 2018-04-06 2023-06-22 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. 3’3’-環状ジヌクレオチド
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CN112969505B (zh) 2018-10-31 2023-11-14 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
AU2019413182A1 (en) * 2018-12-26 2021-06-17 Sumitomo Pharma Co., Ltd. Preparation including vaccine adjuvant
DK3934757T3 (da) 2019-03-07 2023-04-17 Inst Of Organic Chemistry And Biochemistry Ascr V V I 2'3'-cykliske dinukleotider og prodrugs deraf
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020204172A1 (ja) 2019-04-05 2020-10-08 大日本住友製薬株式会社 水溶性アジュバント
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US11497808B2 (en) 2019-09-30 2022-11-15 Gilead Sciences, Inc. HBV vaccines and methods treating HBV
US20230031465A1 (en) 2019-12-06 2023-02-02 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ, インコーポレイテッド 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
CN115666632A (zh) * 2020-03-27 2023-01-31 帕斯公司 疟疾传播阻断疫苗
TW202348237A (zh) 2021-05-13 2023-12-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
US20230060354A1 (en) 2021-06-23 2023-03-02 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022297367A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ES2221414T3 (es) 1998-08-27 2004-12-16 Sumitomo Pharmaceuticals Company, Limited Derivados de pirimidina.
AU2004252409A1 (en) 2003-04-10 2005-01-06 3M Innovative Properties Company Methods and compositions for enhancing immune response
CA2535338C (en) 2003-08-14 2013-05-28 3M Innovative Properties Company Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
FR2924024B1 (fr) * 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
MX2011004249A (es) 2008-10-24 2011-07-20 Glaxosmithkline Biolog Sa Derivados de imidazoquinolina lipidados.
FR2937549B1 (fr) * 2008-10-29 2011-04-01 Centre Nat Rech Scient Nanoparticules de derives beta-lactamine
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
JP5206513B2 (ja) 2009-03-12 2013-06-12 オムロンヘルスケア株式会社 機能追加モジュール
EA201101650A1 (ru) * 2009-05-21 2012-07-30 Астразенека Аб Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
EA023536B1 (ru) 2009-08-07 2016-06-30 Глаксосмитклайн Байолоджикалс Са Производные оксоаденина, конъюгированные с фосфо- или фосфонолипидами
CN103118682A (zh) 2010-04-30 2013-05-22 加利福尼亚大学校务委员会 合成tlr7激动剂的磷脂缀合物的用途
DK2606047T3 (en) 2010-08-17 2017-03-27 3M Innovative Properties Co COMPOSITIONS AND FORMULATIONS WITH LIPIDIZED IMMUNE RESPONSE-MODIFIING COMPOUND AND PROCEDURES THEREOF
US20130267532A1 (en) * 2010-11-19 2013-10-10 Shinya Tosaki Cyclic amide compounds and their use in the treatment of disease
WO2012066336A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
WO2012066335A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012067269A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
BR112014006643A2 (pt) * 2011-09-20 2017-04-04 Hoffmann La Roche compostos de imidazopiridina, composições e métodos de uso dos mesmos
SG11201407115XA (en) * 2012-05-18 2014-12-30 Sumitomo Dainippon Pharma Co Ltd Carboxylic acid compounds
AU2016334826B2 (en) 2015-10-07 2020-08-27 Sumitomo Pharma Co., Ltd. Pyrimidine compound

Also Published As

Publication number Publication date
PH12018500755A1 (en) 2018-10-15
CA3001283C (en) 2023-10-10
PL3868741T3 (pl) 2024-01-29
RU2018116351A (ru) 2019-11-07
JP7195398B2 (ja) 2022-12-23
US10632192B2 (en) 2020-04-28
HK1255921A1 (zh) 2019-09-06
MY194902A (en) 2022-12-22
EP3360864A1 (en) 2018-08-15
KR20180056774A (ko) 2018-05-29
CA3001283A1 (en) 2017-04-13
PL3360864T3 (pl) 2021-10-25
TWI718188B (zh) 2021-02-11
HUE055079T2 (hu) 2021-10-28
JP2021001210A (ja) 2021-01-07
JP6769976B2 (ja) 2020-10-14
US20180280499A1 (en) 2018-10-04
HUE064322T2 (hu) 2024-03-28
EP3868741B1 (en) 2023-08-30
KR102651207B1 (ko) 2024-03-25
CN108290845B (zh) 2021-08-03
DK3868741T3 (da) 2023-11-06
JPWO2017061532A1 (ja) 2018-08-02
US11911466B2 (en) 2024-02-27
PT3868741T (pt) 2023-10-19
SG11201802832UA (en) 2018-05-30
EP3868741A1 (en) 2021-08-25
US20210008197A1 (en) 2021-01-14
EP3360864B1 (en) 2021-04-28
US20220226468A1 (en) 2022-07-21
WO2017061532A1 (ja) 2017-04-13
US11266738B2 (en) 2022-03-08
AU2016334826A1 (en) 2018-05-10
RU2018116351A3 (pt) 2020-02-25
RU2759917C2 (ru) 2021-11-18
FI3868741T3 (fi) 2023-10-02
CY1124542T1 (el) 2022-07-22
TW201718518A (zh) 2017-06-01
ES2960724T3 (es) 2024-03-06
JP2022010266A (ja) 2022-01-14
EP3360864A4 (en) 2019-05-29
CN108290845A (zh) 2018-07-17
AU2016334826B2 (en) 2020-08-27
DK3360864T3 (da) 2021-06-14
ES2870679T3 (es) 2021-10-27

Similar Documents

Publication Publication Date Title
HK1255921A1 (zh) 嘧啶化合物
GB201510019D0 (en) Compounds
IL250022A0 (en) New converted pyrimidine compounds
HK1255832A1 (zh) 吡喃並二吡啶化合物
HUE054351T2 (hu) Vegyületek
GB201521524D0 (en) Compound
GB201508747D0 (en) Compounds
AP2016009506A0 (en) Pyrimidine compound
GB201508864D0 (en) Compounds
SG10201913525QA (en) Pyrimidine derivative
EP3372588A4 (en) pyrimidine
GB201510493D0 (en) Compounds
PT3630729T (pt) Composto de pirimidina
GB201518950D0 (en) Compound
GB201508857D0 (en) Compounds
GB201503926D0 (en) Compounds
GB201501115D0 (en) Compounds
HK1251574A1 (zh) 四氫噁庚英吡啶化合物
GB201520391D0 (en) Compound
GB201520393D0 (en) Compound
GB201509303D0 (en) Compound
GB201511387D0 (en) Compounds
GB201510910D0 (en) Compounds
GB201510760D0 (en) Compounds
GB201508866D0 (en) Compounds